Initially, GLP-1R agonists were thought to be limited to T2D treatment, but it has become clear that these drugs have the potential to treat other diseases such as obesity, CVD, dementia and NAFLD2,7,12,77,103. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.